Tiziana Life Sciences (LON:TILS)(NASDAQ:TLSA) CEO Dr Kunwar Shailubhai tells Proactive London's Andrew Scott they're accelerating a potential treatment for COVID-19 alongside a unique method of delivering the inhaled version of the drug.
As part of the fast-track process, he says the company has signed an agreement with STC Biologics for the good manufacturing practice (GMP) production of TZLS-501, a class of monoclonal antibody (mAb) called an anti-interleukin-6 receptor, or anti-IL6R for short.
Tiziana is also working with a firm called Sciarra Laboratories on a unique technology that sends the drug directly to the lungs using a handheld inhaler or nebuliser.